Cordis Trufill Embolic System Approval Is Fledgling Neurovascular Unit's First
This article was originally published in The Gray Sheet
Executive Summary
Cordis Neurovascular plans to launch the Trufill n-butyl cyanoacrylate (n-BCA) liquid embolic system for treatment of cerebral arteriovenous malformations (AVMs) the week of Oct. 2 following FDA approval of the neurovascular glue Sept. 26.